Blog

What if ‘No Response’ Becomes ‘No Recurrence’ in Colorectal Cancer Treatment? – CancerWorld

Yeva Margaryan/LinkedIn

Apr 1, 2025, 12:18

What if ‘No Response’ Becomes ‘No Recurrence’ in Colorectal Cancer Treatment? – CancerWorld

CancerWorld shared a post on LinkedIn:

“What if ‘no response’ becomes ‘no recurrence’?

For years, patients with microsatellite-stable (MSS) Colorectal Cancer – nearly 80% of all CRC cases-have heard the same message: Immunotherapy doesn’t work for you.

But a new wave of data is challenging that narrative.

In this issue of CancerWorld, we explore a quietly revolutionary shift. A next-generation immunotherapy duo – botensilimab and balstilimab – is showing early signs of doing what many thought impossible: shrinking tumors, preventing recurrence, and, in some cases, even avoiding surgery.

One Phase 2 trial showed 29% of MSS patients had complete pathological responses.

Another found 100% were recurrence-free at follow-up.

This isn’t just data-it’s months of life regained, milestones made possible, and hope where there was none.

We dive into the science, the skepticism, and the human stories behind this development, because in oncology, progress isn’t just measured in percentages. It’s measured in birthdays, graduations, and goodbyes that were never needed.

Read the full cover story.”

Yeva Margaryan, Managing Editor at CancerWorld, shared a post by CancerWorld, adding:

“We dive into the science, the skepticism, and the human stories behind this development, because in oncology, progress isn’t just measured in percentages. It’s measured in birthdays, graduations, and goodbyes that were never needed.”